Boston Family Office LLC Sells 3,980 Shares of Moderna, Inc. (NASDAQ:MRNA)

Boston Family Office LLC lessened its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 42.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,362 shares of the company’s stock after selling 3,980 shares during the period. Boston Family Office LLC’s holdings in Moderna were worth $223,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. abrdn plc boosted its stake in Moderna by 28.1% in the 4th quarter. abrdn plc now owns 315,912 shares of the company’s stock valued at $12,842,000 after purchasing an additional 69,360 shares during the period. Y Intercept Hong Kong Ltd grew its stake in shares of Moderna by 30.9% in the third quarter. Y Intercept Hong Kong Ltd now owns 101,159 shares of the company’s stock valued at $6,760,000 after acquiring an additional 23,881 shares in the last quarter. Spire Wealth Management increased its position in Moderna by 2,150.4% during the fourth quarter. Spire Wealth Management now owns 23,224 shares of the company’s stock worth $966,000 after acquiring an additional 22,192 shares during the period. Geode Capital Management LLC boosted its holdings in Moderna by 2.6% in the 3rd quarter. Geode Capital Management LLC now owns 7,069,580 shares of the company’s stock valued at $470,670,000 after purchasing an additional 178,115 shares during the period. Finally, Proficio Capital Partners LLC grew its position in shares of Moderna by 4,418.9% during the 4th quarter. Proficio Capital Partners LLC now owns 147,360 shares of the company’s stock worth $6,127,000 after purchasing an additional 144,099 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Price Performance

Shares of MRNA opened at $27.16 on Wednesday. The business has a 50-day moving average of $34.43 and a 200-day moving average of $43.55. Moderna, Inc. has a 1 year low of $26.80 and a 1 year high of $170.47. The company has a market capitalization of $10.50 billion, a price-to-earnings ratio of -2.93 and a beta of 1.86.

Wall Street Analyst Weigh In

MRNA has been the subject of several recent research reports. Argus cut Moderna from a “buy” rating to a “hold” rating in a research note on Wednesday, December 18th. JPMorgan Chase & Co. reduced their target price on Moderna from $40.00 to $33.00 and set an “underweight” rating on the stock in a report on Friday, March 21st. Berenberg Bank raised their price target on Moderna from $33.00 to $42.00 and gave the stock a “hold” rating in a research report on Thursday, January 16th. Morgan Stanley reduced their price objective on shares of Moderna from $70.00 to $38.00 and set an “equal weight” rating on the stock in a research note on Wednesday, January 15th. Finally, Royal Bank of Canada restated a “sector perform” rating and issued a $40.00 target price on shares of Moderna in a research report on Tuesday, February 18th. Four investment analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $59.00.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.